Semaglutide + metformin

Semaglutide + metformin has been studied in 2 papers since 2025: none in people yet, 1 in cells; 1 in the past year. No study of it in people or animals has been published yet. The newest story, Nov 9, 2026: “Diabetes medicines linked to better blood sugar than metformin”.

Intervention

2 papers study it110 more mention it6 findingsUpdated

PubChemPubChemChEBIChEBI

19 new papers in 30 daysSee all 112 papers on semaglutide + metformin

At a glance

The findings reach people, from one lab or study. 2 independent labs in 4 countries.

“At 8 months, the patient showed substantial weight loss, which amounted to 13.8 kg (percent total body weight loss: 20.95%)”
Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long ArmReports (MDPI)2026doi:10.3390/reports9010075

None of its findings points the other way.

Cells and humans: a single group. Worms or flies and mice: nothing yet.
  • 2 independent labs in 4 countries
  • Funders: Italian Government Ministry of Health and 2 more
  • Cells1

What did studies of semaglutide + metformin find?

6

Studies of semaglutide + metformin measured 6 outcomes, among them hepatic steatosis, insulin resistance and glycated hemoglobin.

Hepatic steatosis

downin humans1

1 study
  1. Semaglutide + metformin decreases hepatic steatosis in humans (single patient with partial Xq deletion).

    “showed the disappearance of the sonographic characteristics suggestive of mild-to-moderate hepatic steatosis”

    Human trialsingle patient with partial Xq deletionlivermetformin 500 mg/day; semaglutide up to 1.7 mg weekly6 monthsfemalesn = 1

    Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm

    Reports (MDPI)

More on Hepatic steatosis

Insulin resistance

downin humans1

1 study
  1. Semaglutide + metformin decreases insulin resistance in humans (single patient with partial Xq deletion).

    “normalization of markers of insulin sensitivity and insulin resistance (QUICKI, HOMA-IR and TyG index)”

    Human trialsingle patient with partial Xq deletionmetformin 500 mg/day; semaglutide up to 1.7 mg weekly5 monthsfemalesn = 1

    Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm

    Reports (MDPI)

More on Insulin resistance

Glycated hemoglobin

downin humans1

1 study
  1. Semaglutide + metformin decreases glycated hemoglobin in humans (single patient with partial Xq deletion) (0.3 percentage-point reduction).

    “improvement of prediabetes (0.3-percentage-point reduction in glycated hemoglobin [HbA1c] values)”

    Human trialsingle patient with partial Xq deletionmetformin 500 mg/day; semaglutide up to 1.7 mg weekly5 monthsfemalesn = 1

    Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm

    Reports (MDPI)

More on Glycated hemoglobin

Body weight

downin humans1

1 study
  1. Semaglutide + metformin decreases body weight in humans (single patient with partial Xq deletion, as adjunct to lifestyle intervention) (13.8 kg; 20.95% total body weight loss).

    “At 8 months, the patient showed substantial weight loss, which amounted to 13.8 kg (percent total body weight loss: 20.95%)”

    Human trialsingle patient with partial Xq deletion, as adjunct to lifestyle interventionmetformin 500 mg/day; semaglutide up to 1.7 mg weekly8 monthsfemalesn = 1

    Semaglutide Plus Low-Dose Metformin Combination Therapy for the Treatment of Obesity and Prediabetes in a Woman with Partial Deletion of the X Chromosome Long Arm

    Reports (MDPI)

Glucose-stimulated insulin secretion

upin cells1

1 study
  1. Semaglutide + metformin improves glucose-stimulated insulin secretion in cells after HG-HL stimulation.

    “the combination treatments demonstrated superior restoration of glucose-stimulated insulin secretion (GSIS) functionality compared to 1 mM metformin, 10 nM semaglutide, and 10 nM tirzepatide”

    Cellsafter HG-HL stimulation1 mM metformin with 10 nM semaglutide48 h

    Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study

    International journal of molecular sciences

Apoptosis

downin cells1

1 study
  1. Semaglutide + metformin decreases apoptosis in cells (HG-HL conditions).

    “significantly enhances the effects of 10 nM semaglutide and 10 nM tirzepatide on HG-HL-induced apoptosis and dysregulated cell cycle”

    CellsHG-HL conditions1 mM metformin with 10 nM semaglutide48 h

    Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study

    International journal of molecular sciences

More on Apoptosis

Latest

Dec 2025: 4Jan 2026: 0Feb 2026: 6Mar 2026: 8Apr 2026: 2May 2026: 2Jun 2026: 8Jul 2026: 6Aug 2026: 6Sep 2026: 5Oct 2026: 11Nov 2026: 1068 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Diabetes medicines linked to better blood sugar than metformin

Normal blood sugar returned in 37.3% of recipients versus 29.3% taking metformin in a matched comparison of adults with prediabetes and obesity.Normal blood sugar returned in 37.3% of recipients versus 29.3% taking metformin in a matched comparison of adults with prediabetes and obesity.

Cohort · 256,492 peopleDiabetes mellitus
AHA Scientific Sessions 2026 Abstract

Diabetes drugs linked to fewer deaths in young adults

Among young adults with type 2 diabetes, semaglutide users had a one-year relative risk of death of 0.416 compared with metformin users.Among young adults with type 2 diabetes, semaglutide users had a one-year relative risk of death of 0.416 compared with metformin users.

Cohort studyType 2 diabetes
AHA Scientific Sessions 2026 Abstract

Diabetes drugs linked to lower risk of muscle wasting

Users of one drug class had a 23–29% lower relative risk than metformin users over 12 months in an observational analysis.Users of one drug class had a 23–29% lower relative risk than metformin users over 12 months in an observational analysis.

Cohort · 871,884 peopleType 2 diabetes

See all 112 papers on semaglutide + metformin